Enabling discovery, safety and

production of tomorrow's therapeutics

NASDAQ: HBIO

Q1'24 Earnings Presentation

Jim Green, Chairman, President & CEO

Jennifer Cote, CFO & Treasurer

May 7, 2024

Forward-Looking Statements and Non-GAAP Financial Information

Forward-Looking Statements

This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions or statements that do not relate to historical matters. Forward-looking statements include, but are not limited to, information concerning expected future financial and operational performance including revenues, gross margins, earnings, cash and debt position, growth and the introduction of new products, and the strength of the Company's market position and business model. Forward-looking statements are not guarantees of future performance and involve known and unknown uncertainties, risks, assumptions, and contingencies, many of which are outside the Company's control. Risks and other factors that could cause the Company's actual results to differ materially from those described its forward-looking statements include those described in the "Risk Factors" section of the Company's most recently filed Annual Report on Form 10-K as well as in the Company's other filings with the Securities and Exchange Commission. Forward-looking statements are based on the Company's expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to reflect any change in expectations, even as new information becomes available.

Use of Non-GAAP Financial Information

This document includes non-GAAP financial information including one or more of adjusted operating income (loss), adjusted operating margin, adjusted net income (loss), adjusted EBITDA, adjusted EBITDA margin, adjusted diluted earnings (loss) per share, foreign exchange adjusted revenue, and net debt. We believe that this non-GAAP financial information provides investors with an enhanced understanding of the underlying operations of the business. For the periods presented, these non-GAAP financial measures have excluded certain expenses and income resulting from items that we do not believe are representative of the underlying operations of the business. Items excluded include stock-based compensation, amortization of intangibles related to acquisitions, other operating expenses, loss on equity securities, income taxes and the tax impact of the reconciling items. Management believes that this non-GAAP financial information is important in comparing current results with prior period results and is useful to investors and financial analysts in assessing the Company's operating performance. Non-GAAP historical financial statement information included herein is accompanied by a reconciliation to the nearest corresponding GAAP measure which is included as exhibits below.

With respect to non-GAAPforward-looking measures, we provide an outlook for adjusted EBITDA margin. Many of the items that we exclude from this forward-looking measure calculation are less capable of being controlled or reliably predicted by management. These items could cause the forward-looking measures presented in our outlook statements to vary materially from our GAAP results.

The non-GAAP financial information provided in this presentation should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP and may be different than other companies' non-GAAP financial information.

2

CEO Summary: Q1'24 Highlights

Strong gross margin performance and focus on efficiency to support ongoing investments in growth

Income Statement Components ($ in millions except percentages)

Q1' 2024

Q1'2023

Revenue

24.5

30.0

Gross Margin

14.8

18.3

% of Revenue

60.3%

61.2%

Operating (Loss) Profit

(2.3)

1.7

% of Revenue

-9.3%

5.8%

Adjusted Operating Profit*

1.2

4.4

% of Revenue

4.8%

14.8%

Adjusted EBITDA*

1.6

4.8

% of Revenue

6.6%

15.9%

* Non-GAAP measure, see Appendix for reconciliation to GAAP financial measures

3

Q1'24 Revenue by Geography

As Reported

Americas

  • Overall:Down 6.6% as reported
  • Pre-clinical:Slow in Covid related Respiratory products
  • CMT:Growth in advanced cell based systems
  • Academics/NIH: Slow - lack of budget clarity
  • Pharma and CRO: Still keeping tight strings

EMEA

  • Overall:Down 16% reported, includes 1% FX headwind
  • Pre-clinical:General slowing on tight budgets
  • CMT:modest slowing
  • Macro:Spending slower with higher interest rates; Ukraine funding affecting government spend

APAC

  • Overall:Down 35.4% reported vs record PY
  • Pre-clinical:Continued down on tight budgets
  • CMT:Academics remained down significantly from government funded timing for academic research
  • Macro:Improving outlook for second half on China stimulus announcement

* Non-GAAP measure

4

New Product Introductions: Focused on Commercialization

Established base platform targets market growth; exciting new growth opportunities in bio-production and cellular

STRENGTHEN THE BASE

EXPAND TO

BIO-PRODUCTION

INNOVATE CELLULAR

PRECLINICAL

  • Extend leadership in telemetry with the introduction of SoHo Shared Housing telemetry family of implants

Introduced latest Ponemah software integrating

VivaMARS high-capacity behavioral testing with our industry

leading GLP data management and reporting system

Showcased VivaMARS at SfN and SoT expanding our

addressable market into neuro pharmacology applications

  • Fortify leading position in cellular/molecular/inhalation- respiration technologies for research/discovery
  • Continue to expand field service offerings

CMT

  • Adapted our well known BTX electroporation family to cGMP bioproduction applications
  • Released our GLP/cGMP compliant Amino Acid Analyzer for Biopharma bioproduction, adapted from our leading AAA clinical analyzer

CMT-

ORGANOIDS

  • Launched the Mesh MEA Organoid Platform at SfN

Showcased Mesh MEA at Society for Toxicology

  • Initial applications in research and biopharma discovery for neuro, exploring in-vitro safety applications

~85% of FY23 Rev

~10% of FY23 Rev

~5% of FY23 Rev

5

6

Financials

6

Q1'24 Performance vs. Q1'23 (GAAP except where noted)

$ in millions except

REVENUE

GROSS MARGIN

ADJUSTED EBITDA*

per share data

$4.8

$1.6

DILUTED (LOSS) EARNINGS

CASH FLOW FROM OPERATIONS

NET DEBT*

PER SHARE

GAAP

Adjusted*

Q1'24

Q1'23

Q1'24

Q1'23

* Non-GAAP measure, see Appendix for reconciliation to GAAP financial measures

7

8

Outlook

8

2024 Full Year Outlook: 'A Tale of Two Halves'

For FY2024, we expect:

  • Revenues approximately flat for the full year vs. prior year
  • Weakness in the first half versus a strong prior year comparison
  • Second half growth versus both first half of 2024 and the second half of 2023, supported by new product commercializations and expected improvements in China
  • Gross margins in the 60% range
  • Adjusted EBITDA margins to the mid-teens

9

10

Appendix

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Harvard Apparatus Regenerative Technology Inc. published this content on 07 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 May 2024 11:06:17 UTC.